Cargando…
Breathing new life into an old target: pulmonary disease drugs for Parkinson’s disease therapy
Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson’s disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the...
Autores principales: | Abdelmotilib, Hisham, West, Andrew B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649055/ https://www.ncbi.nlm.nih.gov/pubmed/29052536 http://dx.doi.org/10.1186/s13073-017-0483-4 |
Ejemplares similares
-
Neurotrophic factor therapy for Parkinson's disease: past, present and future
por: Sullivan, Aideen M., et al.
Publicado: (2016) -
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
por: McFarthing, Kevin, et al.
Publicado: (2022) -
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2023 Update
por: McFarthing, Kevin, et al.
Publicado: (2023) -
Combination therapy using GDNF and cell transplant in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022) -
Highlight—Epigenetics Virtual Issue: New Findings Amid Old Controversies
por: McGrath, Casey
Publicado: (2022)